Arbutus Biopharma Corporation (ABUS) Income Statement
ABUS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsABUS revenue and net income
Where ABUS's revenue goes
2025Each bar shows an amount and its share of revenue. ABUS kept −237.9% of revenue as net income.
ABUS profit margins
ABUS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +128.2% | −28.8% | +15.3% | −5.5% |
| Gross profit | +122.3% | −29.4% | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ABUS quarterly EPS vs estimates
Arbutus Biopharma beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 12, 2026.
ABUS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.1M | $6.2M | $18.1M | $39.0M | $11.0M | $6.9M | $6.0M | $5.9M | $10.7M | $1.5M |
| Cost of revenue | $363,000 | $1.4M | $73.7M | $1.4M | $1.8M | $47.5M | $57.6M | $57.9M | $62.7M | $61.3M |
| Gross profit | $13.7M | $6.2M | $18.1M | $39.0M | $11.0M | −$40.6M | −$51.6M | −$52.0M | −$52.0M | −$59.8M |
| Research & development | $25.2M | $54.0M | $73.7M | $84.4M | $65.5M | $49.3M | $57.6M | $57.9M | $62.7M | $61.3M |
| Sales, general & admin | $15.9M | $22.1M | $23.9M | $17.8M | $17.1M | $14.8M | $17.7M | $16.0M | $16.1M | $39.4M |
| Total operating expenses | $40.8M | $82.5M | $96.2M | $104.5M | $84.5M | $17.2M | $92.3M | $76.1M | $80.8M | $101.8M |
| Operating income | −$27.1M | −$76.3M | −$78.1M | −$65.5M | −$73.5M | −$57.8M | −$143.9M | −$89.8M | −$110.9M | −$491.6M |
| Interest income | $4.1M | $6.6M | $5.2M | $2.2M | $127,000 | $741,000 | $2.1M | $3.0M | $1.5M | $1.4M |
| Interest expense | $97,000 | $137,000 | $459,000 | $1.7M | $2.9M | $4.0M | $2.1M | $200,000 | $261,000 | $1.4M |
| Income before taxes | −$33.5M | −$69.9M | −$72.8M | −$65.0M | −$76.2M | −$63.7M | −$166.4M | −$61.4M | −$108.7M | −$489.1M |
| Income taxes | — | — | −$1 | $4.4M | $1.1M | $1.5M | −$12.7M | −$4.3M | −$24.3M | −$105.0M |
| Net income | −$33.5M | −$69.9M | −$72.8M | −$69.5M | −$76.2M | −$63.7M | −$153.7M | −$57.1M | −$84.4M | −$384.1M |
| EBITDA | −$33.0M | −$68.4M | −$71.0M | −$61.9M | −$71.6M | −$57.8M | −$162.2M | −$59.0M | −$106.4M | −$488.1M |
| EPS (diluted) | −$0.24 | −$0.53 | −$0.55 | −$0.57 | −$1.00 | −$1.16 | −$2.28 | −$1.79 | −$1.98 | −$2.77 |
| Gross margin | 97.4% | 100.0% | 100.0% | 100.0% | 100.0% | −586.7% | −858.3% | −881.4% | −486.0% | −3,986.7% |
| Operating margin | −192.1% | −1,236.7% | −430.5% | −167.8% | −669.1% | −836.1% | −2,394.0% | −1,522.0% | −1,036.4% | −32,773.3% |
| Net margin | −237.9% | −1,133.0% | −401.6% | −178.0% | −693.9% | −922.0% | −2,557.4% | −967.8% | −788.8% | −25,606.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $179.1M | $1.1M | $529,000 | $10.7M | $1.8M | $1.6M | $1.3M | $1.7M | $1.5M | $2.1M | $4.7M |
| Cost of revenue | $0 | $11,000 | $11,000 | $11,000 | $11,000 | $9.0M | $8.8M | $0 | $356,000 | $15.4M | $17.6M | $369,000 |
| Gross profit | $1.0M | $179.1M | $1.0M | $518,000 | $10.7M | −$7.2M | −$7.2M | $1.3M | $1.7M | $1.5M | −$15.4M | $4.7M |
| Research & development | $2.9M | $4.1M | $5.0M | $5.8M | $5.5M | $9.0M | $8.8M | $14.3M | $15.6M | $15.4M | $17.6M | $20.2M |
| Sales, general & admin | $3.9M | $5.9M | $3.7M | $3.1M | $3.3M | $5.8M | $8.4M | $4.5M | $7.9M | $5.7M | $5.1M | $5.8M |
| Total operating expenses | $7.0M | $10.0M | $8.7M | $8.8M | $9.3M | $27.5M | $6.7M | $22.8M | $23.3M | $20.9M | $5.3M | $26.2M |
| Operating income | −$6.0M | $169.1M | −$7.6M | −$8.3M | $1.5M | −$34.7M | −$13.9M | −$21.4M | −$21.6M | −$19.4M | −$20.7M | −$21.6M |
| Interest income | $842,000 | $815,000 | $877,000 | $952,000 | $1.0M | $1.2M | $1.5M | $1.7M | $1.8M | $1.5M | $1.5M | $1.5M |
| Interest expense | $18,000 | $17,000 | $18,000 | $23,000 | $28,000 | $28,000 | $30,000 | $29,000 | $34,000 | $44,000 | $44,000 | $46,000 |
| Income before taxes | −$5.1M | $169.7M | −$3.8M | −$7.7M | $2.5M | −$24.5M | −$12.5M | −$19.7M | −$19.8M | −$17.9M | −$19.3M | −$20.1M |
| Income taxes | — | — | — | — | — | — | — | — | −$1 | −$1 | $1.1M | −$369,000 |
| Net income | −$5.1M | $169.7M | −$3.8M | −$7.7M | $2.5M | −$24.5M | −$12.5M | −$19.7M | −$19.8M | −$17.9M | −$19.3M | −$20.1M |
| EBITDA | −$5.1M | $169.7M | −$3.7M | −$7.7M | $2.6M | −$24.2M | −$15.3M | −$19.4M | −$19.4M | −$17.5M | −$20.2M | −$19.7M |
| EPS (diluted) | −$0.03 | $1.19 | −$0.01 | −$0.06 | $0.01 | −$0.18 | −$0.10 | −$0.14 | −$0.15 | −$0.14 | −$0.12 | −$0.16 |
| Gross margin | 100.0% | 100.0% | 99.0% | 97.9% | 100.0% | −407.9% | −459.7% | 100.0% | 100.0% | 100.0% | −718.8% | 100.0% |
| Operating margin | −588.2% | 94.4% | −727.3% | −1,567.7% | 13.9% | −1,964.7% | −885.2% | −1,601.2% | −1,250.5% | −1,263.9% | −967.2% | −462.8% |
| Net margin | −507.2% | 94.7% | −357.4% | −1,463.5% | 23.5% | −1,390.4% | −796.2% | −1,472.5% | −1,146.9% | −1,166.8% | −900.3% | −431.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ABUS's financial statements (latest annual report filed March 23, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ABUS financial results
In fiscal year 2025 (ended December 31, 2025), Arbutus Biopharma reported revenue of $14.1 million, up 128.2% from the year before. It had a net loss of $33.5 million, a net profit margin of −237.9%. Diluted earnings per share came to −$0.24. Over five years revenue grew at an average rate of 15.3% a year.
See the ABUS stock overview for the latest quote and news, or the ABUS chart for price history and technical indicators.
ABUS income statement FAQ
What is Arbutus Biopharma's annual revenue?
Arbutus Biopharma reported total revenue of $14.1 million for fiscal year 2025, which ended on December 31, 2025. That was up 128.2% from $6.2 million the previous year.
Is Arbutus Biopharma profitable?
No. Arbutus Biopharma reported a net loss of $33.5 million in fiscal 2025, a net profit margin of −237.9%; its operating margin was −192.1%.
What is Arbutus Biopharma's gross margin?
Arbutus Biopharma's gross margin was 97.4% in fiscal 2025: for every $100 of revenue, Arbutus Biopharma kept $97 after the direct cost of its products and services.
How much does Arbutus Biopharma spend on research and development?
Arbutus Biopharma spent $25.2 million on research and development in fiscal 2025, 179.2% of revenue.
How fast is Arbutus Biopharma growing?
Revenue grew 15.3% a year on average over the last five fiscal years, from $6.9 million to $14.1 million.
What are Arbutus Biopharma's earnings per share?
Arbutus Biopharma earned $-0.24 per diluted share in fiscal 2025, compared with $-0.53 a year earlier.
When will Arbutus Biopharma report its next earnings?
Arbutus Biopharma is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Arbutus Biopharma's fiscal year end?
Arbutus Biopharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 23, 2026.